CoChat

In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy

Xin, Tianqing, Cheng, Li, Zhou, Chuchao, Zhao, Yimeng, Hu, Zhenhua, Wu, Xiaoyan · 2022 · Frontiers in Oncology
Cited by 110

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

Chimeric antigen receptor T cell (CAR-T cell) therapy has shown impressive success in the treatment of hematological malignancies, but the systemic toxicity and complex manufacturing process of current autologous CAR-T cell therapy hinder its broader applications. Universal CAR-T cells have been developed to simplify the production process through isolation and editing of allogeneic T cells from healthy persons, but the allogeneic CAR-T cells have recently encountered safety concerns, and clinical trials have been halted by the FDA. Thus, there is an urgent need to seek new ways to overcome the barriers of current CAR-T cell therapy. In-vivo CAR-T cells induced by nanocarriers loaded with CAR-genes and gene-editing tools have shown efficiency for regressing leukemia and reducing systemic toxicity in a mouse model. The in-situ programming of autologous T-cells avoids the safety concerns of allogeneic T cells, and the manufacture of nanocarriers can be easily standardized. Therefore, the in-vivo induced CAR-T cells can potentially overcome the abovementioned limitations of current CAR-T cell therapy. Here, we provide a review on CAR structures, gene-editing tools, and gene delivery techniques applied in immunotherapy to help design and develop new in-vivo induced CAR-T cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fonc.2022.809754

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Research works printed but not linked: 116

  1. Ramos, 2016, CAR-T Cell Therapy for Lymphoma, Annu Rev Med, 67, 10.1146/annurev-med-051914-021702 · DOI · Paper page
  2. Mohanty, 2019, CAR T Cell Therapy: A New Era for Cancer Treatment (Review), Oncol Rep, 42, 10.3892/or.2019.7335 · DOI · Paper page
  3. Fiorenza, 2021, CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success, BioDrugs, 35, 281, 10.1007/s40259-021-00477-8 · DOI
  4. Kersten, 2020, CD19-Directed CAR T-Cell Therapy in B-Cell NHL, Curr Opin Oncol, 32, 10.1097/CCO.0000000000000668 · DOI
  5. Qualls, 2021, Optimizing CAR T Cell Therapy in Lymphoma, Hematol Oncol, 39, 10.1002/hon.2844 · DOI
  6. Sheth, 2021, Taming the Beast: CRS and ICANS After CAR T-Cell Therapy for ALL, Bone Marrow Transplant, 56, 10.1038/s41409-020-01134-4 · DOI · Paper page
  7. Xu, 2018, Toward Precision Manufacturing of Immunogene T-Cell Therapies, Cytotherapy, 20, 10.1016/j.jcyt.2017.12.007 · DOI
  8. Nawaz, 2020, Nanotechnology and Immunoengineering: How Nanotechnology can Boost CAR-T Therapy, Acta Biomater, 109, 21, 10.1016/j.actbio.2020.04.015 · DOI
  9. Gong, 2021, Nanomaterials for T-Cell Cancer Immunotherapy, Nat Nanotechnol, 16, 25, 10.1038/s41565-020-00822-y · DOI · Paper page
  10. Zhao, 2018, Universal CARs, Universal T Cells, and Universal CAR T Cells, J Hematol Oncol, 11, 132, 10.1186/s13045-018-0677-2 · DOI · Paper page
  11. Perez, 2020, Off-the-Shelf Allogeneic T Cell Therapies for Cancer: Opportunities and Challenges Using Naturally Occurring "Universal" Donor T Cells, Front Immunol, 11, 10.3389/fimmu.2020.583716 · DOI
  12. Townsend, 2020, Paving the Way Towards Universal Treatment With Allogenic T Cells, Immunol Res, 68, 63, 10.1007/s12026-020-09119-7 · DOI
  13. Wagner, 2021, Immunogenicity of CAR T Cells in Cancer Therapy, Nat Rev Clin Oncol, 18, 10.1038/s41571-021-00476-2 · DOI · Paper page
  14. Graham, 2018, Allogeneic CAR-T Cells: More Than Ease of Access, Cells, 7, 155, 10.3390/cells7100155 · DOI · Paper page
  15. Locke, 2021, First-In-Human Data of ALLO-501A, an Allogeneic Chimeric Antigen Receptor (CAR) T-Cell Therapy and ALLO-647 in Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): ALPHA2 Study, J Clin Oncol, 39, 10.1200/JCO.2021.39.15_suppl.2529 · doi:10.1200/jco.2021.39.15_suppl.2529
  16. Smith, 2017, In Situ Programming of Leukaemia-Specific T Cells Using Synthetic DNA Nanocarriers, Nat Nanotechnol, 12, 10.1038/nnano.2017.57 · DOI · Paper page
  17. Agarwal, 2020, In Vivo Generation of CAR T Cells Selectively in Human CD4(+) Lymphocytes, Mol Ther, 28, 10.1016/j.ymthe.2020.05.005 · DOI · Paper page
  18. Parayath, 2020, In Vitro-Transcribed Antigen Receptor mRNA Nanocarriers for Transient Expression in Circulating T Cells In Vivo, Nat Commun, 11, 6080, 10.1038/s41467-020-19486-2 · DOI · Paper page
  19. Mhaidly, 2019, The Future: In Vivo CAR T Cell Gene Therapy, Mol Ther, 27, 10.1016/j.ymthe.2019.03.012 · DOI
  20. Chandran, 2019, T Cell Receptor-Based Cancer Immunotherapy: Emerging Efficacy and Pathways of Resistance, Immunol Rev, 290, 10.1111/imr.12772 · DOI · Paper page
  21. Huang, 2020, Recent Advances in CAR-T Cell Engineering, J Hematol Oncol, 13, 86, 10.1186/s13045-020-00910-5 · DOI · Paper page
  22. Muhammad, 2017, CAR T-Cells for Cancer Therapy, Biotechnol Genet Eng Rev, 33, 190, 10.1080/02648725.2018.1430465 · DOI
  23. Schwarzbich, 2017, Cellular Immunotherapy in B-Cell Malignancy, Oncol Res Treat, 40, 10.1159/000481946 · DOI
  24. Zenere, 2019, Optimizing Intracellular Signaling Domains for CAR NK Cells in HIV Immunotherapy: A Comprehensive Review, Drug Discov Today, 24, 10.1016/j.drudis.2019.02.002 · DOI
  25. Jayaraman, 2020, CAR-T Design: Elements and Their Synergistic Function, EBioMedicine, 58, 10.1016/j.ebiom.2020.102931 · DOI · Paper page
  26. Zhang, 2020, CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead, J Immunol Res, 2020, 10.1155/2020/1924379 · DOI
  27. Wang, 2017, New Development in CAR-T Cell Therapy, J Hematol Oncol, 10, 53, 10.1186/s13045-017-0423-1 · DOI · Paper page
  28. Brudno, 2019, Recent Advances in CAR T-Cell Toxicity: Mechanisms, Manifestations and Management, Blood Rev, 34, 45, 10.1016/j.blre.2018.11.002 · DOI · Paper page
  29. Tokarew, 2019, Teaching an Old Dog New Tricks: Next-Generation CAR T Cells, Br J Cancer, 120, 26, 10.1038/s41416-018-0325-1 · DOI · Paper page
  30. Moreno-Cortes, 2021, Chimeric Antigen Receptor T Cell Therapy in Oncology - Pipeline at a Glance: Analysis of the ClinicalTrials.gov Database, Crit Rev Oncol Hematol, 159, 10.1016/j.critrevonc.2021.103239 · DOI
  31. Kim, 2020, Recent Advances in Allogeneic CAR-T Cells, Biomolecules, 10, 263, 10.3390/biom10020263 · DOI
  32. Weinkove, 2019, Selecting Costimulatory Domains for Chimeric Antigen Receptors: Functional and Clinical Considerations, Clin Transl Immunol, 8, 10.1002/cti2.1049 · DOI · Paper page
  33. Albinger, 2021, Current Status and Perspective of CAR-T and CAR-NK Cell Therapy Trials in Germany, Gene Ther, 28, 10.1038/s41434-021-00246-w · DOI · Paper page
  34. 2016, From CARs to TRUCKs and Beyond: Safely En Route to Adoptive T-Cell Therapy for Cancer, EBioMedicine, 14, 1, 10.1016/j.ebiom.2016.11.037 · DOI
  35. Dragon, 2020, CAR-T Cells and TRUCKs That Recognize an EBNA-3C-Derived Epitope Presented on HLA-B*35 Control Epstein-Barr Virus-Associated Lymphoproliferation, J Immunother Cancer, 8, 10.1136/jitc-2020-000736 · DOI
  36. Hombach, 2016, Superior Therapeutic Index in Lymphoma Therapy: CD30(+) CD34(+) Hematopoietic Stem Cells Resist a Chimeric Antigen Receptor T-Cell Attack, Mol Ther, 24, 10.1038/mt.2016.82 · DOI
  37. Sentman, 2016, Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice, J Immunol, 197, 10.4049/jimmunol.1600769 · DOI · Paper page
  38. Teeling, 2006, The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20, J Immunol, 177, 10.4049/jimmunol.177.1.362 · DOI · Paper page
  39. Rose, 1999, Critical Lym-1 Binding Residues on Polymorphic HLA-DR Molecules, Mol Immunol, 36, 10.1016/S0161-5890(99)00083-8 · doi:10.1016/s0161-5890(99)00083-8
  40. Scarfò, 2018, Anti-CD37 Chimeric Antigen Receptor T Cells are Active Against B- and T-Cell Lymphomas, Blood, 132, 10.1182/blood-2018-04-842708 · DOI
  41. Köksal, 2019, Preclinical Development of CD37CAR T-Cell Therapy for Treatment of B-Cell Lymphoma, Blood Adv, 3, 10.1182/bloodadvances.2018029678 · DOI
  42. Ormhøj, 2019, Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma With or Without Cotargeting CD19, Clin Cancer Res, 25, 10.1158/1078-0432.CCR-19-1337 · DOI
  43. Ruella, 2017, Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells, Cancer Discov, 7, 10.1158/2159-8290.CD-16-0850 · DOI · Paper page
  44. Roselli, 2021, Insight Into Next-Generation CAR Therapeutics: Designing CAR T Cells to Improve Clinical Outcomes, J Clin Invest, 131, 10.1172/JCI142030 · DOI
  45. Roberts, 2018, Axicabtagene Ciloleucel, a First-in-Class CAR T Cell Therapy for Aggressive NHL, Leuk Lymphoma, 59, 10.1080/10428194.2017.1387905 · DOI · Paper page
  46. Abramson, 2020, Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma, Transfus Med Rev, 34, 29, 10.1016/j.tmrv.2019.08.003 · DOI
  47. Anderson, 2021, Brexucabtagene Autoleucel: A Novel Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Mantle Cell Lymphoma, Ann Pharmacother, 2, 10.1177/10600280211026338 · DOI
  48. Mikkilineni, 2021, CAR T Cell Therapies for Patients With Multiple Myeloma, Nat Rev Clin Oncol, 18, 71, 10.1038/s41571-020-0427-6 · DOI · Paper page
  49. Pettitt, 2018, CAR-T Cells: A Systematic Review and Mixed Methods Analysis of the Clinical Trial Landscape, Mol Ther, 26, 10.1016/j.ymthe.2017.10.019 · DOI
  50. Vitale, 2020, CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences, Front Oncol, 10, 10.3389/fonc.2020.00849 · DOI
  51. Wei, 2021, Clinical Development of CAR T Cell Therapy in China: 2020 Update, Cell Mol Immunol, 18, 792, 10.1038/s41423-020-00555-x · DOI
  52. Marple, 2020, Improving CAR T-Cells: The Next Generation, Semin Hematol, 57, 10.1053/j.seminhematol.2020.07.002 · DOI
  53. Rafiq, 2020, Engineering Strategies to Overcome the Current Roadblocks in CAR T Cell Therapy, Nat Rev Clin Oncol, 17, 10.1038/s41571-019-0297-y · DOI · Paper page
  54. Schubert, 2021, Side-Effect Management of Chimeric Antigen Receptor (CAR) T-Cell Therapy, Ann Oncol, 32, 34, 10.1016/j.annonc.2020.10.478 · DOI · Paper page
  55. Anderson, 2019, A Review of Chimeric Antigen Receptor T-Cells in Lymphoma, Expert Rev Hematol, 12, 10.1080/17474086.2019.1629901 · DOI
  56. Neelapu, 2019, Managing the Toxicities of CAR T-Cell Therapy, Hematol Oncol, 37, 48, 10.1002/hon.2595 · DOI · Paper page
  57. Gust, 2020, Cytokines in CAR T Cell-Associated Neurotoxicity, Front Immunol, 11, 10.3389/fimmu.2020.577027 · DOI · Paper page
  58. Ying, 2019, A Safe and Potent Anti-CD19 CAR T Cell Therapy, Nat Med, 25, 10.1038/s41591-019-0421-7 · DOI · Paper page
  59. Kennedy, 2020, A Review of Cancer Immunotherapy Toxicity, CA Cancer J Clin, 70, 86, 10.3322/caac.21596 · DOI · Paper page
  60. Tallantyre, 2021, Neurological Updates: Neurological Complications of CAR-T Therapy, J Neurol, 268, 10.1007/s00415-020-10237-3 · DOI
  61. Yu, 2019, Next Generation Chimeric Antigen Receptor T Cells: Safety Strategies to Overcome Toxicity, Mol Cancer, 18, 125, 10.1186/s12943-019-1057-4 · DOI · Paper page
  62. Castellarin, 2020, A Rational Mouse Model to Detect on-Target, Off-Tumor CAR T Cell Toxicity, JCI Insight, 5, 10.1172/jci.insight.136012 · DOI
  63. Parker, 2020, Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies, Cell, 183, 126, 10.1016/j.cell.2020.08.022 · DOI · Paper page
  64. Derlin, 2021, (18)F-FDG PET/CT of Off-Target Lymphoid Organs in CD19-Targeting Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Ann Nucl Med, 35, 10.1007/s12149-020-01544-w · DOI
  65. Hou, 2021, Navigating CAR-T Cells Through the Solid-Tumour Microenvironment, Nat Rev Drug Discov, 20, 10.1038/s41573-021-00189-2 · DOI · Paper page
  66. Martinez, 2019, CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment, Front Immunol, 10, 10.3389/fimmu.2019.00128 · DOI · Paper page
  67. Wagner, 2020, CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality, Mol Ther, 28, 10.1016/j.ymthe.2020.09.015 · DOI · Paper page
  68. Vormittag, 2018, A Guide to Manufacturing CAR T Cell Therapies, Curr Opin Biotechnol, 53, 10.1016/j.copbio.2018.01.025 · DOI · Paper page
  69. Stock, 2019, Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy, Int J Mol Sci, 20, 6223, 10.3390/ijms20246223 · DOI
  70. Bak, 2018, Gene Editing on Center Stage, Trends Genet, 34, 10.1016/j.tig.2018.05.004 · DOI · Paper page
  71. Li, 2020, Applications of Genome Editing Technology in the Targeted Therapy of Human Diseases: Mechanisms, Advances and Prospects, Signal Transduct Target Ther, 5, 1, 10.1038/s41392-019-0089-y · DOI · Paper page
  72. Urnov, 2005, Highly Efficient Endogenous Human Gene Correction Using Designed Zinc-Finger Nucleases, Nature, 435, 10.1038/nature03556 · DOI · Paper page
  73. Chandrasegaran, 2017, Recent Advances in the Use of ZFN-Mediated Gene Editing for Human Gene Therapy, Cell Gene Ther Insights, 3, 33, 10.18609/cgti.2017.005 · DOI
  74. Boch, 2009, Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors, Science, 326, 10.1126/science.1178811 · DOI · Paper page
  75. Barrangou, 2017, A Decade of Discovery: CRISPR Functions and Applications, Nat Microbiol, 2, 17092, 10.1038/nmicrobiol.2017.92 · DOI · Paper page
  76. Mali, 2013, RNA-Guided Human Genome Engineering via Cas9, Science, 339, 10.1126/science.1232033 · DOI · Paper page
  77. Ren, 2017, A Versatile System for Rapid Multiplex Genome-Edited CAR T Cell Generation, Oncotarget, 8, 10.18632/oncotarget.15218 · DOI · Paper page
  78. Gomes-Silva, 2017, CD7-Edited T Cells Expressing a CD7-Specific CAR for the Therapy of T-Cell Malignancies, Blood, 130, 10.1182/blood-2017-01-761320 · DOI · Paper page
  79. Borot, 2019, Gene-Edited Stem Cells Enable CD33-Directed Immune Therapy for Myeloid Malignancies, Proc Natl Acad Sci USA, 116, 10.1073/pnas.1819992116 · DOI
  80. Liu, 2017, CRISPR-Cas9-Mediated Multiplex Gene Editing in CAR-T Cells, Cell Res, 27, 10.1038/cr.2016.142 · DOI · Paper page
  81. Li, 2020, Applications and Explorations of CRISPR/Cas9 in CAR T-Cell Therapy, Brief Funct Genomics, 19, 10.1093/bfgp/elz042 · DOI
  82. Hu, 2021, Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies, Curr Med Sci, 41, 10.1007/s11596-021-2391-5 · DOI
  83. Razeghian, 2021, A Deep Insight Into CRISPR/Cas9 Application in CAR-T Cell-Based Tumor Immunotherapies, Stem Cell Res Ther, 12, 428, 10.1186/s13287-021-02510-7 · DOI
  84. David, 2017, Viral Vectors: The Road to Reducing Genotoxicity, Toxicol Sci, 155, 10.1093/toxsci/kfw220 · DOI · Paper page
  85. Monjezi, 2017, Enhanced CAR T-Cell Engineering Using non-Viral Sleeping Beauty Transposition From Minicircle Vectors, Leukemia, 31, 10.1038/leu.2016.180 · DOI · Paper page
  86. Shi, 2018, A Review on Electroporation-Based Intracellular Delivery, Molecules, 23, 3044, 10.3390/molecules23113044 · DOI · Paper page
  87. Zhang, 2018, Optimized DNA Electroporation for Primary Human T Cell Engineering, BMC Biotechnol, 18, 4, 10.1186/s12896-018-0419-0 · DOI
  88. Chen, 2018, An Artificial Molecular Shuttle Operates in Lipid Bilayers for Ion Transport, J Am Chem Soc, 140, 10.1021/jacs.8b09580 · doi:10.1021/jacs.8b09580
  89. Rajpoot, 2019, Solid Lipid Nanoparticles: A Promising Nanomaterial in Drug Delivery, Curr Pharm Des, 25, 10.2174/1381612825666190903155321 · DOI
  90. Eygeris, 2020, Deconvoluting Lipid Nanoparticle Structure for Messenger RNA Delivery, Nano Lett, 20, 10.1021/acs.nanolett.0c01386 · DOI · Paper page
  91. Wei, 2020, Systemic Nanoparticle Delivery of CRISPR-Cas9 Ribonucleoproteins for Effective Tissue Specific Genome Editing, Nat Commun, 11, 3232, 10.1038/s41467-020-17029-3 · DOI · Paper page
  92. Meneksedag-Erol, 2015, Probing the Effect of miRNA on siRNA-PEI Polyplexes, J Phys Chem B, 119, 10.1021/acs.jpcb.5b00415 · DOI
  93. Ita, 2020, Polyplexes for Gene and Nucleic Acid Delivery: Progress and Bottlenecks, Eur J Pharm Sci, 150, 10.1016/j.ejps.2020.105358 · doi:10.1016/j.ejps.2020.105358
  94. Kazemi Oskuee, 2018, Investigating the Influence of Polyplex Size on Toxicity Properties of Polyethylenimine Mediated Gene Delivery, Life Sci, 197, 10.1016/j.lfs.2018.02.008 · DOI
  95. Hayat, 2019, Gene Delivery Using Lipoplexes and Polyplexes: Principles, Limitations and Solutions, Crit Rev Eukaryot Gene Expr, 29, 29, 10.1615/CritRevEukaryotGeneExpr.2018025132 · DOI
  96. Gao, 2018, Exosomes in Cancer Therapy: A Novel Experimental Strategy, Am J Cancer Res, 8
  97. Dutta, 2021, Exosomes-Based Cell-Free Cancer Therapy: A Novel Strategy for Targeted Therapy, Immunol Med, 44, 10.1080/25785826.2020.1818482 · DOI
  98. Koritzinsky, 2017, Quantification of Exosomes, J Cell Physiol, 232, 10.1002/jcp.25387 · DOI · Paper page
  99. Wu, 2019, Cell Membrane Camouflaged Nanoparticles: A New Biomimetic Platform for Cancer Photothermal Therapy, Int J Nanomed, 14, 10.2147/IJN.S200284 · DOI
  100. Spanjers, 2020, Cell Membrane Coated Particles, Adv Biosyst, 4, 10.1002/adbi.202000174 · DOI
  101. Wang, 2020, Cell Membrane Biomimetic Nanoparticles for Inflammation and Cancer Targeting in Drug Delivery, Biomater Sci, 8, 10.1039/C9BM01392J · DOI · Paper page
  102. Smith, 2020, CAR-T Cell Expansion in a Xuri Cell Expansion System W25, Methods Mol Biol, 2086, 10.1007/978-1-0716-0146-4_11 · DOI
  103. Geethakumari, 2021, Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments, Curr Hematol Malig Rep, 16, 10.1007/s11899-021-00635-3 · DOI
  104. Jayaraman, 2019, Cut-Price CAR-T Cell Therapies Top India's Biotech Agenda, Nat Biotechnol, 37, 10.1038/s41587-019-0346-1 · DOI
  105. Lin, 2019, Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma, J Clin Oncol, 37, 10.1200/JCO.18.02079 · DOI · Paper page
  106. Pfeiffer, 2018, In Vivo Generation of Human CD19-CAR T Cells Results in B-Cell Depletion and Signs of Cytokine Release Syndrome, EMBO Mol Med, 10, 10.15252/emmm.201809158 · DOI · Paper page
  107. Agarwal, 2019, In Vivo Generated Human CAR T Cells Eradicate Tumor Cells, Oncoimmunology, 8, 10.1080/2162402X.2019.1671761 · DOI · Paper page
  108. Huckaby, 2021, Bispecific Binder Redirected Lentiviral Vector Enables In Vivo Engineering of CAR-T Cells, J Immunother Cancer, 9, 10.1136/jitc-2021-002737 · DOI
  109. Nawaz, 2021, AAV-Mediated In Vivo CAR Gene Therapy for Targeting Human T-Cell Leukemia, Blood Cancer J, 11, 119, 10.1038/s41408-021-00508-1 · DOI · Paper page
  110. Santoiemma, 2015, Tumor Infiltrating Lymphocytes in Ovarian Cancer, Cancer Biol Ther, 16, 10.1080/15384047.2015.1040960 · DOI · Paper page
  111. Siegler, 2018, Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy, Hum Gene Ther, 29, 10.1089/hum.2017.243 · DOI
  112. Agliardi, 2021, Intratumoral IL-12 Delivery Empowers CAR-T Cell Immunotherapy in a Pre-Clinical Model of Glioblastoma, Nat Commun, 12, 444, 10.1038/s41467-020-20599-x · DOI · Paper page
  113. Mollanoori, 2018, CRISPR/Cas9 and CAR-T Cell, Collaboration of Two Revolutionary Technologies in Cancer Immunotherapy, an Instruction for Successful Cancer Treatment, Hum Immunol, 79, 10.1016/j.humimm.2018.09.007 · DOI
  114. Salas-Mckee, 2019, CRISPR/Cas9-Based Genome Editing in the Era of CAR T Cell Immunotherapy, Hum Vaccin Immunother, 15, 10.1080/21645515.2019.1571893 · DOI
  115. Dai, 2019, Standardizing CAR-T Therapy: Getting it Scaled Up, Biotechnol Adv, 37, 10.1016/j.biotechadv.2018.12.002 · DOI
  116. Ho, 2019, Dissection of Gastric Cancer Heterogeneity for Precision Oncology, Cancer Sci, 110, 10.1111/cas.14191 · DOI

Cited by

Metadata

Authors
Xin, T., Cheng, L., Zhou, C., Zhao, Y., Hu, Z., & Wu, X.
Venue
Frontiers in Oncology
Published
2022-02-10
Volume
12
ISSN
2234-943X
Cited by
110
References
20

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.